ClinicalTrials.gg
Not yet recruitingNCT06528392ESPSUpdated Apr 11, 2025

Efgartigimod for Stiff Person Syndrome (ESPS)

A Phase 2 interventional study of Efgartigimod in Stiff-Person Syndrome, sponsored by University of South Florida. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by University of South Florida · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Stiff-Person Syndrome with a site in United States — 4 open to participants now, 5 under way, 1 of them phase 3. Stiff-Person Syndrome · United States.

Planned enrollment
8th of 10
10 · median 24
Started
2025
with 1 other
Phase 2
4 of 12
1 open now
Registered
9th of 12
by date
Lead sponsor
1 of 12
University of South Florida

Among the 12 studies in Stiff-Person Syndrome with a site in United States, this one is the 8th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2025, is one of 4 in phase 2, and was the 9th registered.

Stiff-Person Syndrome

20 studies on the registry are indexed under Stiff-Person Syndrome; 8 are open to participants now.

Browse Stiff-Person Syndrome studies →

Open to participants now

4 of the 12 studies in Stiff-Person Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Stiff-Person Syndrome studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Stiff-Person Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to examine the proportion of patients with stiff person syndrome with no worsening in stiffness and/or spasms while on efgartigimod-hyaluronidase (EFD) when compared to their current treatment. The main questions it aims to answer are:

  • proportion of patients with stiff person syndrome with no worsening in DSI and HSS scores
  • whether there are changes in laboratory values, vital signs, electrocardiogram, or depression, and suicide risk during the trial, as well as the incidence of any adverse events.

Participants will come to the clinic up to 18 times and have up to 5 phone call visits during the course of the trial. During these visits a variety of measures will be collected, including blood samples, neurological and physical exams, patient reported outcomes on stiffness, spasms, depression, and suicide risk.

03

Conditions studied

  • Stiff-Person Syndrome

Browse trials for

Keywords

  • Stiff-Person Syndrome
  • Efgartigimod
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80, men and women, capable of giving .
  2. Must have unexplained stiffness of limb and axial (trunk) muscles and involuntary striated muscle spasms.
  3. DSI and HHS must be >=2 (to allow for detection of improvement).
  4. Presence of serum (or CSF) anti-GAD antibodies regardless of titers.
  5. Stable dosage for at least two months before screening visit with antispasmodics (muscle relaxants, benzodiazepines, baclofen).
  6. Women with children bearing potential must be willing to use highly effective method during and for a minimum of 90 days after the last dose of IP.

Exclusion criteria

Exclusion Criteria:

1. Exclusionary conditions:

1a. type 1 DM

1b. Cancer, except basal cell skin cancer

1c. Infections: , or C, active infection not sufficiently resolved in the investigator's opinion

1d. Serum IgG (\<6 g/L) at screening

1e. pregnancy/breast feeding. 2. Exclusionary medications: rituximab within 6 months of screening. 3. IVIG or PLEX treatment 4 weeks prior to screening. 4. History of any type of solid organ or bone marrow transplant.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    subcutaneous Efgartigimod-hyaluronidase (EFG)

    Participants with GAD65-antibody positive SPS will be given subcutaneous Efgartigimod-hyaluronidase (EFG).

    Biological: Efgartigimod

Interventions

  • BiologicalEfgartigimod alfaStudies of Efgartigimod alfaEfgartigimod alfa pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Efgartigiomd-hyaluroidase (EFG) is a neonatal Fc receptor (FcRn) inhibitor, which blocks the recycling of Immunoglobulin G (IgG), including pathogenic IgG

06

What researchers measure

Primary outcomes

  1. Distribution of Stiffness Index (DSI)

    DSI is a validated indicator or stiffness. Scores range from 0 to 6 and reflect the extent of stiffness. One point is given for stiffness in each of the following areas: lower trunk, upper trunk, legs, arms, face and abdomen.

    Time frame: From enrollment to the end of treatment at week 13

  2. heightened sensitivity score (HSS)

    HSS measures changes in the frequency of spasms. Scores range from 1 to 7; one point given for each source or type of spasm: unexpected noises, visual stimuli, somatosensory stimuli, voluntary activities, emotional upset or stress, no specific stimuli, or nocturnal spasms.

    Time frame: From enrollment to end of treatment at week 13

Secondary outcomes

  1. Proportion of patients with SPS who are treatment responders

    Proportion of patients with SPS who are treatment responders, defined as: \>= 2 points reduction in the distribution of stiffness index (DSI) AND \>= 1 point reduction in heightened sensitivity score (HSS)

    Time frame: enrollment to end of 13 weeks

  2. The duration of time patients maintain responder status

    A responder is defined as one having \>= 2 points reduction in the distribution of stiffness index (DSI) AND \>= 1 point reduction in heightened sensitivity score (HSS)

    Time frame: from enrollment to end of treatment at week 13

  3. Modified Rankin Scale

    Time frame: From enrollment to end of treatment at week 13

07

Study locations

1 site
  • University of South Florida, Carol and Frank Morsani Center for Advanced Healthcare
    Tampa, Florida 33612, United States
    • Jessica D Shaw, MPH · Contactjessshaw@usf.edu · 813-974-9413
    • Tuan H Vu, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — IPD will be shared between designated study sites during the trial. After the end of the trial data may be shared but this has yet to be determined.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Dec 2026, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Jul 30, 2024
StartEst.
Apr 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06528392
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Apr 1, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 11, 2025

Study contacts

Tuan H Vu, MD
Contact
tvu6@usf.edu
813-974-9413
Jessica D Shaw, MPH
Contact
jessshaw@usf.edu
813-974-9413
Tuan H Vu, MD
principal investigator · University of South Florida

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion